这是演示店铺,请务下单付款,避免造成你的财物损失。

为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!

Cemiplimab (anti-PD-1)

功能和特点
  • 规格或纯度: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
  • 应用: ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt
  • 反应种属: Human
  • 亚型: Human IgG4
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
C412010-1mg
1mg 期货 Stock Image
C412010-5mg
5mg 期货 Stock Image
C412010-10mg
10mg 期货 Stock Image

基本信息

产品名称 Cemiplimab (anti-PD-1)
别名 Libtayo; REGN-2810; cemiplimab-rwlc; 西米普利单抗; CD279 antigen; CD279; hPD-1; PD1; PD-1; PD1hPD-l; PDCD1; programmed cell death 1; programmed cell death protein 1; Protein PD-1; SLEB2; CD279 antibody; CD279 antigen antibody; hPD 1 antibody; hPD l antibody; hP
英文别名 Libtayo; REGN-2810; cemiplimab-rwlc; CD279 antigen; CD279; hPD-1; PD1; PD-1; PD1hPD-l; PDCD1; programmed cell death 1; programmed cell death protein 1; Protein PD-1; SLEB2; CD279 antibody; CD279 antigen antibody; hPD 1 antibody; hPD l antibody; hPD-1 anti
规格或纯度 Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
特异性 PDCD1
应用 ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt
反应种属 Human

产品属性

抗体类型 Primary antibody
Format Whole IgG
亚型 Human IgG4
轻链亚型 Kappa
SDS-PAGE 26.0 kDa (Light Chain) & 49.9 kDa (Heavy Chain), under reducing conditions; 169.6 kDa, under non-reducing conditions.
纯化方法 Protein A purified
来源 CHO supernatant
物理外观 Liquid
防腐剂 No
浓度 Lot by Lot
储存温度 -80℃储存,避免反复冻融
运输条件 超低温冰袋运输
稳定性与储存 Store at -80℃ for 18 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS编号和信息 1801342-60-8

质检证书(COA)

质检报告(COA)

输入批号以搜索COA:

产品问答

产品问答

登录提交问题 Hover me 请先登录再提交问题
您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, Huang TT, Poueymirou WT, Esau L, Meola M et al..  (2014)  Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice..  Proc Natl Acad Sci USA,  111  (14):  (5153-8).  [PMID:24706856]
2. Falchook GS, Leidner R, Stankevich E, Piening B, Bifulco C, Lowy I, Fury MG.  (2016)  Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810..  J Immunother Cancer,  (13):  (70).  [PMID:27879972]
3. Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q et al..  (2017)  Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice..  Mol Cancer Ther,  16  (5):  (861-870).  [PMID:28265006]
4. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS et al..  (2018)  PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma..  N Engl J Med,  379  (4):  (341-351).  [PMID:29863979]

计算器